Immune evasion from natural killer cells by non small cell lung carcinoma

非小细胞肺癌自然杀伤细胞的免疫逃避

• 批准号: 453387
• 负责人: Boudreau Jeanette E
• 金额: $ 4.37万
• 依托单位: Dalhousie University (Nova Scotia)
• 依托单位国家: 加拿大
• 项目类别: Operating Grants
• 财政年份: 2021
• 资助国家: 加拿大
• 起止时间: 2021-03-01 至 2023-03-01
• 项目状态: 已结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=453387&lang=en
• 关键词: Biomarkers; Immunotherapy Targets; Oncolytic Viruses &Amp

Although treatment of patients with non small cell lung carcinoma has improved over the last decade – most notably with checkpoint-based immunotherapies – the majority of patients relapse with resistant and disseminated disease. This highlights that curre

尽管非小细胞肺癌患者的治疗在过去十年中有所改善--最显著的是基于检查点的免疫疗法--但大多数患者复发时患有耐药和播散性疾病。这突出显示了Curre